Current approaches against Alzheimer's disease in clinical trials
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFLA |
Texto Completo: | http://repositorio.ufla.br/jspui/handle/1/36716 |
Resumo: | Alzheimer's disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Currently, this disease represents one of the uppermost human issues, both from the medical and economic point of view. Interest in the discovery of a drug for AD is enormous. However, despite the long-term and worldwide effort for a more effective therapy, the only available treatment is a symptomatic use of acetylcholinesterase inhibitors (AChEIs) and memantine. New therapeutic approaches as well as those based on cholinergic or amyloid theory have not brought the desired benefits yet. Thus, the question is whether an effective drug for this progressive disease will ever be developed or whether people will have to rely only on prevention and minimize risk factors of AD. |
id |
UFLA_65c376a2265264c4afd448b14134ddd7 |
---|---|
oai_identifier_str |
oai:localhost:1/36716 |
network_acronym_str |
UFLA |
network_name_str |
Repositório Institucional da UFLA |
repository_id_str |
|
spelling |
Current approaches against Alzheimer's disease in clinical trialsAlzheimer's disease - TreatmentAcetylcholinesterase inhibitorsDoença de Alzheimer - TratamentoInibidores da acetilcolinesteraseAlzheimer's disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Currently, this disease represents one of the uppermost human issues, both from the medical and economic point of view. Interest in the discovery of a drug for AD is enormous. However, despite the long-term and worldwide effort for a more effective therapy, the only available treatment is a symptomatic use of acetylcholinesterase inhibitors (AChEIs) and memantine. New therapeutic approaches as well as those based on cholinergic or amyloid theory have not brought the desired benefits yet. Thus, the question is whether an effective drug for this progressive disease will ever be developed or whether people will have to rely only on prevention and minimize risk factors of AD.Sociedade Brasileira de Química2019-09-06T13:07:56Z2019-09-06T13:07:56Z2016info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfKUCA, K. et al. Current approaches against Alzheimer's disease in clinical trials. Journal of the Brazilian Chemical Society, São Paulo, v. 27, n. 4, p. 641-649, 2016.http://repositorio.ufla.br/jspui/handle/1/36716Journal of the Brazilian Chemical Societyreponame:Repositório Institucional da UFLAinstname:Universidade Federal de Lavras (UFLA)instacron:UFLAhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessKuca, KamilSoukup, OndrejMaresova, PetraKorabecny, JanNepovimova, EugenieKlimova, BlankaHonegr, JanRamalho, Teodorico C.França, Tanos C. C.eng2019-09-06T13:07:56Zoai:localhost:1/36716Repositório InstitucionalPUBhttp://repositorio.ufla.br/oai/requestnivaldo@ufla.br || repositorio.biblioteca@ufla.bropendoar:2019-09-06T13:07:56Repositório Institucional da UFLA - Universidade Federal de Lavras (UFLA)false |
dc.title.none.fl_str_mv |
Current approaches against Alzheimer's disease in clinical trials |
title |
Current approaches against Alzheimer's disease in clinical trials |
spellingShingle |
Current approaches against Alzheimer's disease in clinical trials Kuca, Kamil Alzheimer's disease - Treatment Acetylcholinesterase inhibitors Doença de Alzheimer - Tratamento Inibidores da acetilcolinesterase |
title_short |
Current approaches against Alzheimer's disease in clinical trials |
title_full |
Current approaches against Alzheimer's disease in clinical trials |
title_fullStr |
Current approaches against Alzheimer's disease in clinical trials |
title_full_unstemmed |
Current approaches against Alzheimer's disease in clinical trials |
title_sort |
Current approaches against Alzheimer's disease in clinical trials |
author |
Kuca, Kamil |
author_facet |
Kuca, Kamil Soukup, Ondrej Maresova, Petra Korabecny, Jan Nepovimova, Eugenie Klimova, Blanka Honegr, Jan Ramalho, Teodorico C. França, Tanos C. C. |
author_role |
author |
author2 |
Soukup, Ondrej Maresova, Petra Korabecny, Jan Nepovimova, Eugenie Klimova, Blanka Honegr, Jan Ramalho, Teodorico C. França, Tanos C. C. |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Kuca, Kamil Soukup, Ondrej Maresova, Petra Korabecny, Jan Nepovimova, Eugenie Klimova, Blanka Honegr, Jan Ramalho, Teodorico C. França, Tanos C. C. |
dc.subject.por.fl_str_mv |
Alzheimer's disease - Treatment Acetylcholinesterase inhibitors Doença de Alzheimer - Tratamento Inibidores da acetilcolinesterase |
topic |
Alzheimer's disease - Treatment Acetylcholinesterase inhibitors Doença de Alzheimer - Tratamento Inibidores da acetilcolinesterase |
description |
Alzheimer's disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Currently, this disease represents one of the uppermost human issues, both from the medical and economic point of view. Interest in the discovery of a drug for AD is enormous. However, despite the long-term and worldwide effort for a more effective therapy, the only available treatment is a symptomatic use of acetylcholinesterase inhibitors (AChEIs) and memantine. New therapeutic approaches as well as those based on cholinergic or amyloid theory have not brought the desired benefits yet. Thus, the question is whether an effective drug for this progressive disease will ever be developed or whether people will have to rely only on prevention and minimize risk factors of AD. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016 2019-09-06T13:07:56Z 2019-09-06T13:07:56Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
KUCA, K. et al. Current approaches against Alzheimer's disease in clinical trials. Journal of the Brazilian Chemical Society, São Paulo, v. 27, n. 4, p. 641-649, 2016. http://repositorio.ufla.br/jspui/handle/1/36716 |
identifier_str_mv |
KUCA, K. et al. Current approaches against Alzheimer's disease in clinical trials. Journal of the Brazilian Chemical Society, São Paulo, v. 27, n. 4, p. 641-649, 2016. |
url |
http://repositorio.ufla.br/jspui/handle/1/36716 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Química |
publisher.none.fl_str_mv |
Sociedade Brasileira de Química |
dc.source.none.fl_str_mv |
Journal of the Brazilian Chemical Society reponame:Repositório Institucional da UFLA instname:Universidade Federal de Lavras (UFLA) instacron:UFLA |
instname_str |
Universidade Federal de Lavras (UFLA) |
instacron_str |
UFLA |
institution |
UFLA |
reponame_str |
Repositório Institucional da UFLA |
collection |
Repositório Institucional da UFLA |
repository.name.fl_str_mv |
Repositório Institucional da UFLA - Universidade Federal de Lavras (UFLA) |
repository.mail.fl_str_mv |
nivaldo@ufla.br || repositorio.biblioteca@ufla.br |
_version_ |
1815439042408349696 |